LCIV - ETF AI Analysis
Top Page
Logan Capital International ETF (LCIV)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Energy Holdings
Several of the largest energy companies in the portfolio have shown strong recent performance, helping support the ETF’s returns.
Broad Sector Mix
Holdings spread across financials, consumer stocks, health care, energy, and other sectors help reduce the impact of weakness in any single industry.
Exposure to Established Global Companies
Top positions include large, well-known international firms in areas like pharmaceuticals, energy, and financial services, which can provide stability and diversification versus a purely domestic portfolio.
Negative Factors
High Expense Ratio
The fund’s management fee is relatively high for an ETF, which can eat into long-term returns compared with lower-cost options.
Heavy U.S. Concentration
Most of the portfolio is invested in U.S. assets, limiting the benefits of global diversification despite being labeled an international strategy.
Mixed Performance and Small Asset Base
Recent performance has been slightly negative and the fund manages a relatively small amount of assets, which may indicate limited investor adoption and potentially higher trading costs.
LCIV vs. SPDR S&P 500 ETF (SPY)
AUM19.38M
RegionDeveloped Markets
Expense Ratio0.99%
BetaN/A
IssuerLogan
Inception DateSep 30, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume278
30 Day Avg. Volume248
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LCIV Summary
The Logan Capital International ETF (LCIV) is an actively managed fund that invests in large, well-established companies outside the United States, giving investors broad international exposure rather than tracking a single index. It spreads money across many sectors, including financials, health care, energy, and consumer companies. Well-known holdings include Roche and Shell, which are major global players in medicine and energy. Someone might invest in LCIV to diversify beyond U.S. stocks and seek long-term growth and dividends from overseas markets. A key risk is that international stocks can be volatile and may rise or fall differently than the U.S. market.
How much will it cost me?This ETF has an expense ratio of 0.99%, which means you’ll pay about $9.90 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed rather than simply tracking a broad market index.
What would affect this ETF?This ETF could benefit if developed markets outside the U.S. grow steadily, interest rates stabilize or fall (supporting financials), and global demand for healthcare and energy stays strong, which would help major holdings like Roche, Novartis, Shell, BP, and TotalEnergies. On the other hand, it could face challenges if international economies slow, banks come under pressure from stricter regulations or higher funding costs, or if energy prices drop or new climate policies hurt large oil and gas companies, all of which could weigh on returns.
LCIV Top 10 Holdings
LCIV is leaning heavily on Europe’s energy giants, with Shell, BP, TotalEnergies, and Equinor all rising and effectively powering the fund’s recent results. On the flip side, big pharma names like Novartis, Roche, and especially Sanofi have been losing steam, acting as a brake on performance. Financials such as Allianz and media player Publicis are more steady to mixed, offering some balance but not stealing the spotlight. Overall, this is a developed-markets ex-U.S. play, with a clear tilt toward European energy and healthcare leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roche Holding | 3.35% | $647.91K | $344.30B | 18.46% | 74 Outperform | |
| Shell | 3.11% | $602.10K | $286.43B | 40.27% | 78 Outperform | |
| BP | 3.07% | $594.61K | $120.05B | 38.10% | 68 Neutral | |
| TotalEnergies SE | 3.00% | $580.55K | €175.29B | 60.18% | 78 Outperform | |
| Novartis | 2.94% | $569.29K | $262.82B | 10.55% | 80 Outperform | |
| Equinor ASA | 2.93% | $566.16K | $104.51B | 85.31% | 69 Neutral | |
| Sanofi | 2.92% | $564.79K | $96.20B | -16.68% | 75 Outperform | |
| Publicis Groupe SA | 2.75% | $532.33K | $27.36B | 14.48% | 80 Outperform | |
| Allianz SE Unsponsored ADR | 2.69% | $520.44K | $177.07B | 9.82% | 79 Outperform | |
| ― | 2.69% | $520.33K | ― | ― | ― |
LCIV Technical Analysis
Positive
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LCIV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LCIV.
LCIV Peer Comparison
Comparison Results
Performance Comparison
LCIV
Logan Capital International ETF
24.90
0.32
1.30%
INEQ
Columbia International Equity Income Etf
―
―
―
RWIN
Rayliant NxtGen Multifactor International Equity ETF
―
―
―
FFDI
Fidelity Fundamental Developed International ETF
―
―
―
JINT
Janus Henderson International Core Alpha ETF
―
―
―
PRXI
Praxis Impact International ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents